Trial of Intravenous Immune Globulin in Dermatomyositis
- PMID: 36198179
- DOI: 10.1056/NEJMoa2117912
Trial of Intravenous Immune Globulin in Dermatomyositis
Abstract
Background: Intravenous immune globulin (IVIG) for the treatment of dermatomyositis has not been extensively evaluated.
Methods: We conducted a randomized, placebo-controlled trial involving patients with active dermatomyositis. The patients were assigned in a 1:1 ratio to receive IVIG at a dose of 2.0 g per kilogram of body weight or placebo every 4 weeks for 16 weeks. The patients who received placebo and those without confirmed clinical deterioration while receiving IVIG could enter an open-label extension phase for another 24 weeks. The primary end point was a response, defined as a Total Improvement Score (TIS) of at least 20 (indicating at least minimal improvement) at week 16 and no confirmed deterioration up to week 16. The TIS is a weighted composite score reflecting the change in a core set of six measures of myositis activity over time; scores range from 0 to 100, with higher scores indicating greater improvement. Key secondary end points included at least moderate improvement (TIS ≥40) and major improvement (TIS ≥60), and change in score on the Cutaneous Dermatomyositis Disease Area and Severity Index.
Results: A total of 95 patients underwent randomization: 47 patients were assigned to the IVIG group, and 48 to the placebo group. At 16 weeks, 79% of the patients in the IVIG group (37 of 47) and 44% of those in the placebo group (21 of 48) had a TIS of at least 20 (difference, 35 percentage points; 95% confidence interval, 17 to 53; P<0.001). The results with respect to the secondary end points, including at least moderate improvement and major improvement, were generally in the same direction as the results of the primary end-point analysis, except for the change in creatine kinase level (an individual core measure of the TIS), which did not differ meaningfully between the two groups. Over 40 weeks, 282 treatment-related adverse events occurred in the IVIG group, including headache (in 42% of patients), pyrexia (in 19%), and nausea (in 16%). A total of 9 serious adverse events that were considered to be related to IVIG occurred, including 6 thromboembolic events.
Conclusions: In this 16-week trial involving adults with dermatomyositis, the percentage of patients with a response of at least minimal improvement based on a composite score of disease activity was significantly greater among those who received IVIG than among those who received placebo. IVIG was associated with adverse events, including thromboembolism. (Funded by Octapharma Pharmazeutika; ProDERM ClinicalTrials.gov number, NCT02728752.).
Copyright © 2022 Massachusetts Medical Society.
Comment in
-
Intravenous Immune Globulin Therapy in Dermatomyositis.N Engl J Med. 2022 Oct 6;387(14):1320-1321. doi: 10.1056/NEJMe2209117. N Engl J Med. 2022. PMID: 36198183 No abstract available.
-
Protection against Omicron from Vaccination and Previous Infection. Reply.N Engl J Med. 2023 Jan 5;388(1):96. doi: 10.1056/NEJMc2214627. Epub 2022 Dec 21. N Engl J Med. 2023. PMID: 36546676 No abstract available.
-
Trial of Intravenous Immune Globulin in Dermatomyositis.N Engl J Med. 2023 Jan 5;388(1):94. doi: 10.1056/NEJMc2214285. N Engl J Med. 2023. PMID: 36599069 Free PMC article. No abstract available.
-
Trial of Intravenous Immune Globulin in Dermatomyositis. Reply.N Engl J Med. 2023 Jan 5;388(1):94-95. doi: 10.1056/NEJMc2214285. N Engl J Med. 2023. PMID: 36599070 No abstract available.
-
In adults with active dermatomyositis, IV immune globulin improved treatment response at 16 wk vs. placebo.Ann Intern Med. 2023 Feb;176(2):JC22. doi: 10.7326/J22-0111. Epub 2023 Feb 7. Ann Intern Med. 2023. PMID: 36745896 Clinical Trial.
Similar articles
-
Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis ("ProDERM Study").Medicine (Baltimore). 2021 Jan 8;100(1):e23677. doi: 10.1097/MD.0000000000023677. Medicine (Baltimore). 2021. PMID: 33429735 Free PMC article. Clinical Trial.
-
Safety and tolerability of intravenous immunoglobulin in patients with active dermatomyositis: results from the randomised, placebo-controlled ProDERM study.Arthritis Res Ther. 2024 Jan 17;26(1):27. doi: 10.1186/s13075-023-03232-2. Arthritis Res Ther. 2024. PMID: 38233885 Free PMC article. Clinical Trial.
-
Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.ACR Open Rheumatol. 2022 Jun;4(6):486-491. doi: 10.1002/acr2.11414. Epub 2022 Feb 14. ACR Open Rheumatol. 2022. PMID: 35157371 Free PMC article.
-
Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.Cochrane Database Syst Rev. 2017 May 8;5(5):CD003280. doi: 10.1002/14651858.CD003280.pub5. Cochrane Database Syst Rev. 2017. PMID: 28481421 Free PMC article. Review.
-
Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.Cochrane Database Syst Rev. 2012 Aug 15;2012(8):CD003643. doi: 10.1002/14651858.CD003643.pub4. Cochrane Database Syst Rev. 2012. PMID: 22895935 Free PMC article. Review.
Cited by
-
Efficacy and safety of intravenous immunoglobulin therapy in systemic sclerosis: a systematic review.Rheumatol Int. 2024 May 15. doi: 10.1007/s00296-024-05613-5. Online ahead of print. Rheumatol Int. 2024. PMID: 38748220
-
Intravenous Immunoglobulin-Induced Aseptic Meningitis in a Dermatomyositis Patient.Cureus. 2024 Apr 14;16(4):e58242. doi: 10.7759/cureus.58242. eCollection 2024 Apr. Cureus. 2024. PMID: 38745808 Free PMC article.
-
A Review of Antisynthetase Syndrome-Associated Interstitial Lung Disease.Int J Mol Sci. 2024 Apr 18;25(8):4453. doi: 10.3390/ijms25084453. Int J Mol Sci. 2024. PMID: 38674039 Free PMC article. Review.
-
Effectiveness and safety of mycophenolate mofetil and rituximab combination therapy for immune idiopathic myopathies.Arthritis Res Ther. 2024 Apr 3;26(1):79. doi: 10.1186/s13075-024-03310-z. Arthritis Res Ther. 2024. PMID: 38570792 Free PMC article.
-
Novel and potential future therapeutic options in systemic autoimmune diseases.Front Immunol. 2024 Mar 15;15:1249500. doi: 10.3389/fimmu.2024.1249500. eCollection 2024. Front Immunol. 2024. PMID: 38558805 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical